Sun Denied Over US Antitrust Challenge
Indian Firm May Not Appeal Ruling Rejecting Dismissal Bid
Executive Summary
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
You may also be interested in...
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Sun Pharma Challenges US Antitrust Ruling
India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.